Empirical antifungal therapy for persistent fever in patients with neutropenia [1]

Clinical Infectious Diseases

Volumn 32, Issue 2, 2001, Pages 320-321

  Chandrasekar, P H ^a  

^a Henry Ford Health System Division of Infectious Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; FLUCONAZOLE;

ANTIBIOTIC THERAPY; ASPERGILLOSIS; CANDIDIASIS; FEBRILE NEUTROPENIA; LETTER; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT OUTCOME;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLUS; DEOXYCHOLIC ACID; DRUG COMBINATIONS; FEVER; FLUCONAZOLE; HUMANS; MYCOSES; NEUTROPENIA;

EID: 0035245296     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/318455     Document Type: Letter

References (6)

1. Practice guidelines for the treatment of candidiasis
2. A randomized comparison of fluconazole with amphotericin B as empiric antifungal agents in cancer patients with prolonged fever and neutropenia
3. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer
4. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: A pragmatic and randomized clinical trial
5. Early empiric antifungal treatment for febrile neutropenia in patients with hematologic malignancies: Fluconazole versus amphotericin B/5-flucytosine
6. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever